This is a major de-risking event for ARTV. The 71% ACR50 response rate in a highly refractory RA population and FDA alignment on a single Phase 3 trial design significantly reduce clinical and regulatory risk. The ATM suspension removes a dilution overhang. Watch for EULAR 2026 presentations (late-breaking oral) and Phase 3 trial initiation in H2 2026 as the next catalysts. The stock should re-rate on the improved probability of success.
ARTV drugs
ARTV drug pipeline →Price Chart
Executive Summary
Artiva reported Q1 2026 net loss of $23.5M ($0.95/share), slightly wider than the $20.3M loss a year ago, with cash burn reducing the balance to $86.8M (funding into Q2 2027). The headline event is the positive initial Phase 2a clinical data for AlloNK in refractory RA (71% ACR50 at 6 months) and FDA alignment on a single Phase 3 registrational trial design, representing a major de-risking catalyst for a pre-revenue biotech. The company also suspended its ATM facility, removing near-term dilution overhang.
Key Financial Metrics
Key Facts
- Net loss of $23.5M for Q1 2026 vs $20.3M in Q1 2025; net loss per share $0.95 vs $0.83
- Cash, cash equivalents and investments of $86.8M as of March 31, 2026, expected to fund operations into Q2 2027
- 71% ACR50 response rate in 7 refractory RA patients with 6 months follow-up in company-sponsored Phase 2a basket trial
- FDA alignment on a single Phase 3 registrational RCT in ~150 refractory RA patients; trial initiation planned for H2 2026
- No CRS, ICANS, or treatment discontinuations related to AlloNK reported; Grade 3+ infection rate of 2%
- ATM facility suspended; no further sales of common stock under existing prospectus supplement
- More than 70 autoimmune patients treated with AlloNK across 40+ active clinical sites globally
Financial Impact
Pre-revenue clinical-stage biotech; cash burn of ~$23.5M/quarter; $86.8M cash runway into Q2 2027
Risk Factors
- Phase 3 trial may fail to replicate Phase 2a results in a larger, randomized setting
- Official FDA minutes may contain interpretations differing from company's understanding
- Cash runway only into Q2 2027; may need additional financing before Phase 3 data readout in H2 2028
- Competition from auto-CAR-T, T-cell engagers, and other deep B-cell depleting therapies
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-213239 |
| Document: d38160d8k.htm | 0001193125-26-213239 |
| Document: d38160dex993.htm | 0001193125-26-213239 |
| Document: d38160dex992.htm | 0001193125-26-213239 |
| Document: 0001193125-26-213239-index-headers.html | 0001193125-26-213239 |
| Document: 0001193125-26-213239-index.html | 0001193125-26-213239 |
| Document: 0001193125-26-213239.txt | 0001193125-26-213239 |
| 8-K Data (Synthetic) | 0001193125-26-213239 |
Track record
33 reports on ARTV
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers